Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 9/20 | 0.45 |
| ▸ | JAK3 | P52333 | 4/20 | 0.45 |
| ▸ | KDR | P35968 | 4/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.45 |
| ▸ | BTK | Q06187 | 9/20 | 0.43 |
| ▸ | BMX | P51813 | 2/20 | 0.43 |
| ▸ | BLK | P51451 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | TEC | P42680 | 1/20 | 0.43 |
| ▸ | TXK | P42681 | 1/20 | 0.43 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 6/20 | 0.43 |
| ▸ | RAF1 | P04049 | 3/20 | 0.43 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26165678 | 0.79 | LCK (0.50) | LCKJAK3KDRMAPK14BTK | |
| SCHEMBL26165703 | 0.75 | RAF1 (0.46) | LCKMAPK14BRAFRAF1 | |
| SCHEMBL22625546 | 0.73 | BTK (0.41) | JAK3BTKBMXBLKEGFR | |
| SCHEMBL22612763 | 0.72 | LCK (0.61) | LCKJAK3KDRMAPK14BRAF | |
| SCHEMBL30439800 | 0.72 | LCK (0.61) | LCKJAK3KDRMAPK14BRAF | |
| SCHEMBL22612843 | 0.72 | LCK (0.51) | LCKJAK3KDRMAPK14BRAF | |
| SCHEMBL29427327 | 0.72 | LCK (0.51) | LCKJAK3KDRMAPK14BRAF | |
| SCHEMBL30440409 | 0.72 | LCK (0.54) | LCKJAK3KDRMAPK14BRAF | |
| SCHEMBL29427269 | 0.72 | RAF1 (0.55) | LCKJAK3KDRMAPK14BRAF | |
| SCHEMBL22612830 | 0.72 | LCK (0.54) | LCKJAK3KDRMAPK14BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927111-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200347052-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347052-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, NRAS | LCK 19/4885JAK3 349/4885KDR 113/4885 |
| US-10927111-B2 | Inhibitors of RAF kinases | BRAF, RAF1, NRAS | LCK 19/4885JAK3 349/4885KDR 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.